Medical Oncology

Her2+   

Questions discussed in this category



This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...

How would your treatment change given pCR rates are reportedly much lower in triple positive patients?

How would this change if the patient had metastatic HR+,HER2- breast cancer and now has symptomatic pancytopenia secondary to BM involvement after TCH...

Given the changing landscape of treatment, some patients may have already received capecitabine previously.  Would this impact your treatment rec...

The APT trial reported excellent DFS, OS and RFI for tumors <=3cm but few were smaller T2s (2-3 cm) and few were >70 years old.

It is included in favorable histologies on NCCN, but no mention of how to treat based off HER2 status.

If yes, would you still recommend dual HER2 directed therapy? After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...

Clinical T1c patients were included in the KATHERINE trial that often are treated with adjuvant paclitaxel and trastuzumab

The NEJM 2015 paper by Tolaney et al only included 1.5% of patients with micrometastases.

Would you do this for ER+ patients? According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...

Would you consider using CKD inhibitors upfront in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Hercepti...

Would you consider using ckd inhibitors in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Herceptin? NCCN ...

The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.

Do you ever consider de-escalating or stopping therapy in this situation? What is your approach to this conversation?


Papers discussed in this category


Breast cancer research : BCR, 2009

Cancer cell, 2012-10-16

Cancer cell, 2016-03-14

Cancer discovery, 2016-07

Cancer, 2015-12-15

Lancet (London, England), 2009-12-19

The Lancet. Oncology, 2014-06

The New England journal of medicine, 2012-11-08

J. Clin. Oncol.,

The New England journal of medicine, 2012-01-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10

Journal of gastrointestinal oncology, 2016-08

The New England journal of medicine, 2015-02-19

Cochrane Database Syst Rev, 2008 Apr 16

Eur. J. Cancer, 2013 May 22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01

N Engl J Med, 2015 Jan 8

N. Engl. J. Med.,

The Lancet. Oncology, 2013-10

N. Engl. J. Med., 2017-07-13

The Lancet. Oncology, 2017-06

The New England journal of medicine, 2019-02-14

The Lancet. Oncology, 2016-03

Lancet Oncol., 2017 Feb 24

Eur. J. Cancer, 2017 May 03

N Engl J Med, 2011 Oct 6

Lancet Oncol., 2018 Nov 06

Breast cancer research and treatment, 2018-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01

The Lancet. Oncology, 2017-12

Lancet,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-20

Curr Treat Options Oncol, 2019 Mar 14

Breast Cancer, 2016 Feb 13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01

The Lancet. Oncology, 2018-07

N. Engl. J. Med., 2019 Dec 11

Anticancer Res.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01

The New England journal of medicine, 2018-07-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20

J. Clin. Oncol., 2019 Oct 16